Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Detalles Bibliográficos
Autores principales: de Silva, Madhawa, Itchins, Malinda, Pavlakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214900/
https://www.ncbi.nlm.nih.gov/pubmed/32411778
http://dx.doi.org/10.21037/atm.2020.01.87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214900/
https://www.ncbi.nlm.nih.gov/pubmed/32411778
http://dx.doi.org/10.21037/atm.2020.01.87

Ejemplares similares